MABPRO, a.s.
We are building an immunotherapy platform and companion diagnostics for aggressive, hypoxic tumors using Carbonic Anhydrase IX (CA IX) as the therapeutic target and mechanism of action.
Mission & Vision
To fill the gap in the treatment of oncology diseases / hypoxic tumours with poor prognosis.
To bring hope and increase survival in patients unresponsive to standard oncology treatments.
To deliver new targeted therapies aligned with personalized medicine to improve patient outcomes.
Targeted Tumor Types
Tumors expressing Carbonic Anhydrase IX.
Triple-negative breast cancer (TNBC)
Clear-cell renal-cell carcinoma (ccRCC)
Non-small-cell lung cancer (NSCLC)
Head and neck cancers
Mesothelioma
Advanced Patient Stratification
MABPRO, a.s. coordinates a major, multi-partner, bioinformatics project designed to develop advanced patient stratification capabilities for personalized immunotherapy treatment.
Sophisticated tumor diagnostics
Pre-surgical biochemical and immunological analysis, post-surgical IHC analysis, RNA sequencing, and micro tumor preparation.
Learn MoreBig data analysis and machine learning
Collected data serve as a basis for individual characterization of tumors, including the genetic background, heterogeneity, and therapy sensitivity.
Learn MoreEffective targeting of therapy to the patient
Identification of patients most likely to respond to our treatment is key to maximizing effectiveness, improving outcomes, and ensuring personalization.
Learn MoreBest local clinical and academic partners
A comprehensive network of clinical sites working with experts in basic research, bioinformatics, and technology to support innovation and development.
Learn More
Mechanism of action
CA9hu-1 and CA9hu-2: TWO CUSTOM DESIGNED HUMANIZED IgG1 ANTIBODIES.
CA IX
Bind to the extracellular domain of CA IX and attract NK and T cells.
CA IX
Inhibit CA IX and alter the tumor microenvironment by increasing extracellular pH.
CA IX
Inhibit CA IX and decrease intracellular pH, reducing mTOR signaling.
Seal of Excellence
Recognized as a high-quality project proposal in a highly competitive evaluation process. Awarded with the Horizon Europe Seal of Excellence.
What they said about us
EIC Accelerator Evaluation Quotes
“This very diverse and extremely competent team has definitely capability and needed motivation to implement the innovation proposal and bring it to the market with a great success.”
EIC Accelerator Evaluation Quote
“Their project to develop an advanced patient stratification capabilities for precision medicine is unique and gives a great opportunity for high growth of participants including other European countries and beyond.”
EIC Accelerator Evaluation Quote
“It is breakthrough with a great market opportunity. Targeting hypoxia is an excellent strategy. If it proves its value, will be a game changer for many years to come.”
EIC Accelerator Evaluation Quote
